Cholecystokinin antagonists a new way to improve the analgesia from old analgesics?

Current Pharmaceutical Design

Volumn 10, Issue 3, 2004, Pages 303-314

  McCleane, Gary ^a  

^a Rampark Pain Centre   (United Kingdom)

Author keywords

Cholecystokinin; L 365,260; Neuropathic pain; Opioids; Proglumide

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ALFENTANIL; BENZOTRIPT; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; DEVAZEPIDE; DYNORPHIN A; ENKEPHALIN DERIVATIVE; ITRIGLUMIDE; LORGLUMIDE; LOXIGLUMIDE; MORPHINE; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; N [1 (2 FLUOROPHENYL) 3,4,6,7 TETRAHYDRO 4 OXOPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL] 1H INDOLE 2 CARBOXAMIDE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALOXONE; OPIATE; PD 134 308; PD 135158; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PROGLUMIDE; RB 211; SCOPOLAMINE; SPIROGLUMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANTINOCICEPTION; BILIARY COLIC; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CHOLECYSTOKININ BLOOD LEVEL; CHRONIC PANCREATITIS; CLINICAL TRIAL; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; EXPERIMENTAL ANIMAL; GASTROINTESTINAL TRACT; HUMAN; MOUSE; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; REVIEW; SIDE EFFECT; VISCERAL PAIN;

ANALGESICS; ANIMALS; CHOLECYSTOKININ; CLINICAL TRIALS; DRUG TOLERANCE; DYNORPHINS; ENKEPHALINS; HUMANS; NARCOTICS; PAIN; TIME FACTORS;

EID: 0347286765     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043386419     Document Type: Review

References (106)

1. Boyden EH. Anat Rec 1926; 33: 162.
2. Ivy AC, Oldberg E. A hormone mechanism for gall-bladder contraction and evacuation. Am J Physiol 1928; 86: 599-613.
3. Rehfeld JF. Immunochemical studies on cholecystokinin. J Biol Chem 1978; 253: 4022-30.
4. Muller JE, Straus E, Yalow RS. Cholecystokinin and its COOH terminal octapeptide in the pig brain. Proc Natl Acad Sci USA 1977; 74: 3035-7.
5. Innis RB, Snyder SH. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 1980; 77: 6917-21.
6. Larsson LI, Rehfeld JF. Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Research 1979; 165: 201-18.
7. Schiffmann SN, Vanderhaeghen JJ. Distribution of cells containing mRNA encoding cholecystokinin in the rat central nervous system. J Comparative Neurol 1991; 304 219-33.
8. Linderfors N, Linden A, Brene S, Sedvall G, Persson H. CCK peptides and mRNA in the human brain. Progress Neurobiology 1993; 40: 671-90.
9. Kuwahara T, Kudoh T, Nakano A et al. Species specificity of pharmacological characteristics of CCK B receptors. Neurosci Lett 1993; 158: 1-4.
10. 3H MK329. J Neurosci 1990; 10: 1070-81.
11. Verge VM, Wiesenfeld-Hallin Z, Hokfelt T. Cholecystokinin in mammalian primary sensory neurons and spinal cord: In situ hybridization studies in rat and monkey. Eur J Neurosci 1993; 5: 240-50.
12. Zhang X, Dagerlind A, Elde et al. Marked increase in cholecystokinin B receptor messenger RNA levels in rat dorsal root ganglia after peripheral axotomy. Neuroscience 1993; 57: 227-33.
13. Xu X-J, Puke MJ, Verge VM, Wiesenfeld-Hallin Z, Hughes J, Hokfelt T. Up regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett 1993; 152: 129-32.
14. Bras JM, Laporte A-M, Benoliel JJ et al. Effects of peripheral axotomy on cholecystokinin neurotransmission in the rat spinal cord. J Neurochemistry 1999; 72: 858-67.
15. Gustafsson H, Afrah A, Brodin E, Stiller C-O. Pharmacological characterization of morphine induced in vivo release of cholecystokinin in rat dorsal horn: effects of ion channel blockers. J Neurochemistry 1999; 73: 1145-54.
16. Zhou Y, Sun Y-H, Zhang Z-W, Han J-S. Increased release of immunoreative cholecystokinin octapeptide by morphine and potentiation of mu opioid analgesia by CCK B receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol 1993; 234: 147-54.
17. Wiesenfeld-Hallin ZA, Lucas G de A, Alster P, Xu X-J, Hokfelt T. Cholecystokinin / opioid interactions. Brain Research 1999; 848: 78-89.
18. Zhou X, Bayer BM. Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Research 1993; 625: 139-44.
19. Xu X-J, Alster P, Wu W-P, Hao J-X, Wiesenfeld-Hallin Z. Increased level of cholecystokinin in cerebrospinal fluid is associated with chronic pain-like behaviour in spinally injured rats. Peptides 2001; 22: 1305-8.
20. Kovelowski CJ, Ossipov MH, Sun H, Lai TP, Malan TP, Porreca F. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain 2000; 87L 265-73.
21. Faris PL, Komisaruk BR, Watkins LR, Mayer DJ. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983; 219: 310-2.
22. Schafer M, Zhou L, Stein C. Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue. Neuroscience 1998; 82: 603-11.
23. Watkins LR, Kinscheck LB, Mayer DJ. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Research 1985; 327: 169-80.
24. Suh HW, Kim Y-H, Choi YS, Song DK. Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse. Peptides 1995; 16: 1229-34.
25. Lavigne GJ, Millington WR, Mueller GP. The CCK A and CCK B receptor antagonists, Devazepide and L365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 1992; 21: 119-29.
26. Nichols ML, Bian D, Ossipov MH, Lai J, Porreca F. Regulation of morphine anti allodynic efficacy by cholecystokinin in a rat model of neuropathic pain in rats. J Pharmacol Exp Ther 1995; 275: 1339-45.
27. Coudore-Civiale M-A, Courteix C, Fialip J, Boucher M, Eschalier A. Spinal effect of the cholecystokinin B receptor antagonist CI988 on hyperalgesia, allodynia and morphine induced analgesia in diabetic and mononeuropathic rats. Pain 2000; 88: 15-22.
28. Wiesenfeld-Hallin Z, Xu X-J, Hughes J, Horwell DC, Hokfelt T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci 1990; 87: 7105-9.
29. Singh L, Oles RJ, Field MJ, Atwal P, Woodruff GN, Hunter JC. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine. J Pharmacol 1996; 118: 1317-25.
30. Yamamoto T, Sakashita Y. Differential effects of intrathecally administered morphine and its interaction with cholecystokinin B antagonists on thermal hyperalgesia following two models of experimental mononeuropathy in the rat. Anesthesiology 1999; 90: 1382-91.
31. Zarrindast M-R, Samiee F, Rezayat M. Antinociceptive effect of intracerebroventricular administration of cholecystokinin receptor agonist and antagonist in nerve ligated mice. Pharmacol Ther 2000; 87: 169-73.
32. Bodnar RJ, Paul D, Pasternak GW. Proglumide selectively potentiates supraspinal mu opioid analgesia in mice. Neuropharmacology 1990; 29: 507-10.
33. Dourish CT, Hawley D, Iversen SD. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L365,260. Eur J Pharmacol 1988; 147: 469-72.
34. Fujimoto JM, Schaus AK, Tseng LF. Spinal dynorphin A: possible mediator of antianalgesic action in mice. Neuropharmacology 1990; 29: 609-17.
35. Wang FS, Rady JJ, Fujimoto JM. Elimination of the antianalgesic action of dynorphin A (1-17) by spinal transection in barbital anesthetized mice. J Pharmacol Exp Ther 1994; 268: 873-80.
36. Rady JJ, Holmes BB, Fujimoto JM. Antianalgesic action of dynorphin A mediated by spinal cholecystokinin. Proc Soc Exp Biol Med 1999; 220: 178-83.
37. Wang FS, Fujimoto JM. Pentobarbital administered intracerebroventriculary antagonizes morphine induced antinociception in mice. J Pharmacol Exp Ther 1993; 265: 1361-8.
38. Rady JJ, Lin W, Fujimoto JM. Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin. J Pharmacol Exp Ther 1998; 284: 878-85.
39. Urban MO, Smith DJ, Gebhart GF. Involvement of spinal cholecystokinin B receptors in mediating neurotensin hyperalgesia from the medullary nucleus raphe magnus in the rat. J Pharmacol Exp Ther 1996; 278: 90-8.
40. Urban MO, Smith DJ. Localization of the antinoceptive and antianalgesic effects of neurotensin within the rostral ventromedial medulla. Neurosci Lett 1994; 174: 21-5.
41. Urban MO, Smith DJ. Role of neurotensin in the nucleus raphe magnus in opioid-induced antinociception from the periaqueductal gray. J Pharmacol Exp Ther 1993; 265: 580-6.
42. Gall C, Lauterborn J, Burks D, Serogy K. Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res 1987; 403: 403-8.
43. 5 enkephalin, and dynorphin A (1-8) like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 1990; 55: 1122-30.
44. Fournie-Zaluski MC, Coric P, Turcaud S et al. Mixed inhibitor prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 1992; 35: 2473-81.
45. Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP. Cholecystokinin B antagonists strongly potentate antinociception mediated by endogenous enkeophalins. J Pharmacol Exp Ther 1994; 270: 77-88.
46. La Guen S, Nieto MM, Canestrelli C et al. Pain management by a new series of dual enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK 2 antagonist or methadone. Pain 2003 In Press
47. Vanderah TW, Bernstein RN, Lai JL, Porreca F. Production of naltindole sensitive antinociception by a cholecystokinin (CCK) antagonist and thiorphan: evidence for tonic inhibition of enkephalin release by CCK. Analgesia 1995; 1: 4-6.
48. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 2: 654-7.
49. Grevert P, Albert LH, Goldstein A/ Partial antagonism of placebo analgesia by naloxone. Pain 1983; 16: 129-43.
50. Fields HL, Levine JD. Placebo analgesia - a role for endorphens? Trends Neurosci 1984; 7: 271-3.
51. Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature 1984; 312: 755-6.
52. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996; 64: 535-43.
53. Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995; 346: 1231.
54. Hruby VJ, Agnes RS, Davis P et al. Design of novel peptide ligands that have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sciences 2003;73:699-704.
55. Tang J, Chou J, Iadarola M, Yang H-YT, Costa E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 1984; 23: 715-8.
56. Panerai AE, Rovati LC, Cocco E, Sacerdote P, Mantegazza, P. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain Research 1987; 410: 52-60.
57. Tortorici V, Nogueira L, Salas R, Vanegas H. Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats. Pain 2003; 102: 9-16.
58. Idanpaan-Heikkila JJ, Guilbaud G, Kayser V. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin B receptor antagonist in a rat model of peripheral neuropathy. J Pharmacol Exp Ther 1997; 282: 1366-72.
59. Zarrindast M-R, Nikfar S, Rezayat M. Cholecystokinin receptor mechanism(s) and morphine tolerance in mice. Pharmacology Toxicology 1999; 84: 46-50.
60. Zarrindast M-R, Zabihi A, Rezayat M, Rakhshandeh H, Ghazi-Khansari M, Hosseini R. Effects of caerulein and CCK antagonists on tolerance induced to morphine antinociception in mice. Pharmacol Biochem Behav 1997; 58: 173-8.
61. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK B receptor antagonist L365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990; 176: 35-44.
62. Kissin I, Bright CA, Bradley EL. Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-D-aspartate nitric oxide systems. Anesth Analg 2000; 91: 110-6.
63. Hoffmann O, Wiesenfeld-Hallin Z. The CCK B receptor antagonist CI988 reverses tolerance to morphine in rats. Neuro Report 1994; 5: 2565-8.
64. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 1984; 224: 395-6.
65. Dourish CT, O'Neill MF, Schafer LW, Siegl PK, Iversen SD. The cholecystokinin receptor antagonist Devazepide enhances morphine induced analgesia but not morphine induced respiratory depression in the squirrel monkey. J Phamacol Exp Ther 1990; 255: 1158-65.
66. McCleane GJ. A phase 1 study of the cholecystokinin (CCK) B antagonist L365,260 in human subjects taking morphine for intractable non-cancer pain. Neurosci Lett 2002; 332: 210-2.
67. Price DD, von der Gruen A, Miller J, Rafii A, Price C. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesth Analg 1985; 64: 801-6.
68. Lavigne GJ, Hargreaves KM, Schmidt EA, Dionne RA. Proglumide potentiates morphine analgesia for acute postsurgical pain. Clin Pharmacol Ther 1989; 45: 666-73.
69. Lehmann KA, Schlusener M, Arabatsis P. Failure of proglumide, a cholecystokinin antagonist, to potentiate clinical morphine analgesia. Anesth Analg 1989; 68: 51-6.
70. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain. Anesth Analg 1998; 87: 1117-20.
71. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clin J Pain 2003; 19: 200-1.
72. Bernstein ZP, Yucht S, Battista E, Lema M, Spaulding MB. Proglumide as a morphine adjunct in cancer pain management. J Pain Symptom Mang 1998; 15: 314-20.
73. McCleane GJ. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett 2003; 338: 151-4.
74. McCleane GJ. The cholecystokinin antagonist proglumide reduces analgesic tolerance to morphine in humans with chronic benign pain. Pain Clinic 1999; 11: 309-12.
75. Cantor P, Petronijevic L, Worning H. Plasma cholecystokinin concentrations in patients with advanced chronic pancreatitis. Pancreas 1986; 1: 488-93.
76. Bozkurt T, Adler G, Koop I, Turmer W, Arnold R. Plasma CCK levels in patients with pancreatic insufficiency. Dig Dis Sci 1988; 33: 276-81.
77. Glasbrenner B, Malferheiner P, Piermico O. Gallbladder dynamics in chronic pancreatitis: relationship to exocrine pancreatic function, CCK and PP release. Dig Dis Sci 1993; 38: 482-9.
78. Garces MC, Gomez-Cerezo J, Codoceo R et al. Relationship of basal and postprandial intra duodenal bile acid concentrations and plasma cholecystokinin levels with abdominal pain in patients with chronic pancreatitis. Pancreas 1998; 17: 397-401.
79. Gomez-Cerezo J, Codoceo R, Fernadez-Calle P, Molina F, Tenias JM, Vazquez JJ. Basal and postprandial cholecystokinin values in chronic pancreatitis with and without abdominal pain. Digestion 1991; 48: 134-40.
80. McCleane GJ. The cholecystokinin antagonist proglumide has an analgesic effect in chronic pancreatitis. Pancreas 2000; 21: 324-5.
81. Malesci A, Pezzilli R, D'Amato M, Rovati L. CCK 1 receptor blockade for treatment of biliary colic: a pilot study. Aliment Pharmacol Ther 2003; 18: 333-7.
82. McLaughlin J, Grazia Luca M, Jones MN, D'Amato M, Dockray GJ, Thompson DJ. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology 1999; 116: 46-53.
83. Pahl IR, Koppert W, Enk C et al. Different lipid profiles as constituencies of liquid formula diets do not influence pain perception and the efficacy of opioids in a human model of acute pain and hyperalgesia. Pain 2003; 104: 519-27.
84. Coudore-Civiale MA, Courteix C, Boucher M et al. Potentiation of morphine and clomipramine analgesia by cholecystokinin B antagonist CI988 in diabetic rats. Neurosci Lett 2000; 286: 37-40
85. Lu L, Huang M, Liu Z, Ma L. Cholecystokinin B receptor antagonists attenuate morphine dependence and withdrawal in rats. Neuro Report 2000; 11: 829-32.
86. Lu L, Huang M, Ma L, Li J. Different role of cholecystokinin (CCK) A and CCK B receptors in relapse to morphine dependence in rats. Behav Brain Res 2001; 120: 105-10.
87. Mierderer SE, Lindstaedt H, Kurz K, Mayerhofer R. Efficient treatment of gastric ulcer with proglumide (Milid) in outpatients (double blind trial). Acta Hepatogastroenterol 1979; 26: 314-8.
88. Galeone M, Moise G, Ferrante F, Cacioli D, Casula PL, Bignamini AA. Double blind clinical comparison between a gastrin receptor antagonist, proglumide, and a histamine H2 blocker, cimetidine. Curr Med Res Opinion 1978; 5: 376-82.
89. Rezvani A, Stokes KB, Rhoads DL, Way EL. Proglumide exhibits delta opioid agonist properties. Alchol Drug Res 1987; 7: 135-46.
90. Chang RS, Chen TB, Bock MG et al. Characterization of the binding of [3H] L365,260: a new potent and selective brain cholecystokinin (CCK B) and gastrin receptor antagonist radioligand. Mol Pharmacol 1989; 35: 803-8.
91. Lotti VJ, Chang RS. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK B) ligand: L365,260. Eur J Pharmacol 1989; 162: 273-80.
92. O'Neill MF, Dourish CT, Tye SJ, Iversen SD. Blockade of CCK B receptors by L365,260 induces analgesia in the squirrel monkey. Brain Res 1990; 534; 287-90.
93. Chang RS, Lotti VJ. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 1986;83: 4923-6.
94. Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RS, Clineschmidt BV. In vivo pharmacology of L364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1978; 241: 103-9.
95. Fukamizu Y, Nakajima T, Kimura K et al. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin A receptor antagonist. Arzneimittelforschung 1998; 48: 58-64.
96. Yamamoto T, Nozaki-Taguchi N. The effects of intrathecally administered FK480, a cholecystokinin A receptor antagonist, and YM022,a cholecystokinin B receptor antagonist, on the formalin test in the rat. Anesth Analg 1996; 83: 107-13.
97. Taniguchi H, Yazaki N, Endo T, Nagasaki M. Pharmacological profile of T0632, a novel potent and selective CCK A receptor antagonist, in vitro. Eur J Pharmacol 1996; 304: 147-54.
98. Zhang X, Lucas D de A, Elde R, Wiesenfeld-Hallin Z, Hokfelt T. Effect of morphine on cholecystokinin and mu opioid receptor like immunoreactivities in rat spinal dorsal horn neurons after peripheral axotomy and inflammation. Neuroscience 2000; 95: 197-207.
99. Heinricher MM, McGaraughty S, Tortorici C. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 2001; 85: 280-6.
100. 3H]etorphine binding to rat brain opioid receptor. Life Sci 1989; 45: 117-23.
101. Wang X-J, Han J-S. Modification by cholecystokinin octapeptide of the binding of mu, delta and kappa opioid receptors. J Neurochem 1990; 55: 1379-82.
102. 5]enkephalin antiserum sensitive enhancement of morphine antinociception. Neuro Report 1994; 5: 2601-5.
103. Vanderah TW, Bernstein RN, Yamamura HI, Hruby VJ, Porreca F. Enhancement of morphine antinociception by a CCK B antagonist in mice is mediated via opioid delta receptors. J Pharmacol Exp Ther 1996; 278: 212-9.
104. Onaka T, Luckman SM, Guevara-Guzman R, Ueta Y, Kendrick K, Leng G. Presynaptic actions of morphine: blockade of cholecystokinin induced noradrenaline release in the rat supraoptic nucleus. J Physiol 1995; 482: 69-79
105. Wang J, Ren M, Han J. Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide. Peptides 1992; 13: 947-51.
106. Sullivan AF, Hewett K, Dickenson AH. Differential modulation of alpha-2 adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in rat dorsal horn: an electrophysiological study. Brain Res 1994; 662: 141-7.